85th Annual Congress of the European Atherosclerosis Society 2017
ODYSSEY APPRISE offers insights into the real world use of PCSK9 inhibitor
What do we know about patients receiving a PCSK9 inhibitor in real world practice? In the case of alirocumab, what will be the usual dose regimen? These and other questions were the driver for the ODYSSEY APPRISE study, the first European/Canadian study which focused on…
read more »Posted on 27 April 2017 |
Posted in 85th Annual Congress of the European Atherosclerosis Society 2017
New EAS Consensus Panel Statement: LDL causes ASCVD
85rd Annual Congress of the European Atherosclerosis Society (EAS), April 23-26th, Prague, Czech Republic Yesterday the EAS Consensus Panel published a new Consensus Statement confirming that LDL causes ASCVD. While there has been extensive evidence implicating LDL as a major modifiable cardiovascular risk factor, others…
read more »Posted on 25 April 2017 |
Posted by John Chapman | Posted in 85th Annual Congress of the European Atherosclerosis Society 2017
